KAS
HAE icon

Kestra Advisory Services’s Haemonetics HAE Stock Holding History

Kestra Advisory Services’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-422
Closed -$33.8K – 3654
2025
Q4 		$33.8K Buy
+422
New +$28.4K ﹤0.01% 4210
2021
Q2 		– Sell
-2,855
Closed -$317K – 2017
2021
Q1 		$317K Buy
+2,855
New +$353K ﹤0.01% 1433

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
RRAM
River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Kestra Advisory Services's HAE Position: Q1 2026 in Review

Kestra Advisory Services sold out of Haemonetics (HAE) in Q1 2026, closing a stake of 422 shares — an estimated $33.8K sold.

Kestra Advisory Services first reported a position in HAE in Q1 2021 and held it in 2 quarters. The position peaked at $317K in Q1 2021. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

  • Kestra Advisory Services reported no remaining Haemonetics position as of Q1 2026 after selling out during the quarter.
  • Kestra Advisory Services sold 422 Haemonetics shares in Q1 2026, an estimated $33.8K.
  • Kestra Advisory Services first reported a position in Haemonetics in Q1 2021 and held it in 2 quarters.
  • Kestra Advisory Services's Haemonetics position peaked at $317K in Q1 2021.
  • 324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on Kestra Advisory Services's 13F filing for Q1 2026, filed 30 Apr 2026.